For research use only. Not for therapeutic Use.
Os30, a potent fourth-generation EGFR inhibitor, is a potent EGFRC797S-TK inhibitor with IC50 values of 18 nM and 113 nM for EGFRDel19/T790M/C797S TK and EGFRL858R/T790M/C797S TK, respectively. Os30 can suppress EGFR phosphorylation, arrest at G1 phase and induce the apoptosis of KC-0116 (BaF3-EGFRDel19/T790M/C797S) cells. Os30 shows potent antitumor efficacy on non-small cell lung cancer (NSCLC) with EGFmRC797S mutation[1].
| Catalog Number | I040289 |
| CAS Number | 2998928-68-8 |
| Synonyms | N-[2-[4-(dimethylamino)piperidin-1-yl]-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]methanesulfonamide |
| Molecular Formula | C27H33N7O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C27H33N7O2S/c1-32(2)20-12-15-34(16-13-20)26-10-9-19(17-24(26)31-37(4,35)36)29-27-28-14-11-23(30-27)22-18-33(3)25-8-6-5-7-21(22)25/h5-11,14,17-18,20,31H,12-13,15-16H2,1-4H3,(H,28,29,30) |
| InChIKey | QBVWTVAJGQIBKK-UHFFFAOYSA-N |
| SMILES | CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=CC(=C(C=C4)N5CCC(CC5)N(C)C)NS(=O)(=O)C |
| Reference | [1]. Xiao-Xiao Xi, et al. Modification of osimertinib to discover new potent EGFRC797S-TK inhibitors. Eur J Med Chem. 2023 Dec 5:261:115865. |
